A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

Mastall, Maximilian; Roth, Patrick; Bink, Andrea; Fischer Maranta, Angela; Läubli, Heinz; Hottinger, Andreas Felix; Hundsberger, Thomas; Migliorini, Denis; Ochsenbein, Adrian; Seystahl, Katharina; Imbach, Lukas; Hortobagyi, Tibor; Held, Leonhard; Weller, Michael; Wirsching, Hans-Georg (2024). A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer, 24(1), p. 82. BioMed Central 10.1186/s12885-023-11797-z

[img]
Preview
Text
s12885-023-11797-z.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (954kB) | Preview

BACKGROUND

Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma.

METHODS/DESIGN

GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland.

TRIAL REGISTRATION

NCT05664464. Registered 23 December 2022.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Ochsenbein, Adrian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1471-2407

Publisher:

BioMed Central

Language:

English

Submitter:

Pubmed Import

Date Deposited:

16 Jan 2024 09:49

Last Modified:

30 Jun 2024 02:19

Publisher DOI:

10.1186/s12885-023-11797-z

PubMed ID:

38225589

Uncontrolled Keywords:

Cancer neuroscience Epilepsy Gabapentin Memantine Sulfasalazine

BORIS DOI:

10.48350/191653

URI:

https://boris.unibe.ch/id/eprint/191653

Actions (login required)

Edit item Edit item
Provide Feedback